- Meeting abstract
- Open Access
Glycated hemoglobin follow-up of sis-hiperdia (Muriaé-Minas Gerais, Brazil)
© de Oliveira et al. 2015
- Published: 11 November 2015
- Physical Activity
- Diabetes Mellitus
- Diabetic Patient
- HbA1C Level
The glycated hemoglobin (HbA1C) test, essential for diabetic patients follow-up, measures the concentrations of glycated hemoglobin in the blood, which can indicate, as they increase in proportion to glucose rates, the possibility of complications of the disease. Furthermore, the test points to the risk of Type 2 diabetes mellitus (T2D) development, for concentration values between 5.7% and 6.4%, and confirms its diagnosis if values exceed 6.5% in two different tests. In T2D patients, values above 7% imply heightened risk of microvascular complications and neuropathy. Several factors in the patients' lifestyle affect these values, such as the practice of physical activities, diet and weight control.
To evaluate the progress of T2D patients treated in the institution between January of 2013 and January of 2015, noting the HbA1C control levels.
Review of 361 medical records of the institution, collection and statistical analysis of data. Patients with values of HbA1C below 9%, who are not included in the institution's system, and those who did not return for follow-up appointments, have been excluded from the study. The patients' age, gender and ethnicity were not taken into account.
Of the 361 evaluated patients, 244 (67.59%) showed a decrease in the values of HbA1C; 03 (0.83%) maintained at the same values; 23 (6.37%) exhibited an increase in the values; and only 35 (9.69%) reached values considered as adequate (<7%) at the end of the follow-up. Many patients, 56 (15.51%), abandoned the follow-up after the first appointment.
The follow-up and treatment provided to T2D patients managed to reduce their HbA1C levels in most cases, although small the fraction of those who attained Results considered ideal. The number of patients who exhibited the opposite result, along with those who discontinued the treatment, poses the question of whether through better scrutiny of patients' conditions their chances of success might rise.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.